Journal of the American Academy of Dermatology
Volume 63, Issue 3 , Pages 457-465 , September 2010

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Limited portions of these data were presented at the 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Ontario, Canada, May 3-7, 2008, and the Fifth International Congress on Psoriasis: From Gene to Clinic, London, United Kingdom, December 4-6, 2008.

  • Richard G. Langley, MD

      Affiliations

    • Dalhousie University, Halifax, Nova Scotia, Canada
    • ,
  • Steven R. Feldman, MD

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, North Carolina
    • ,
  • Chenglong Han, PhD

      Affiliations

    • Worldwide Health Economics, Johnson & Johnson Pharmaceutical Services LLC, Horsham, Pennsylvania
    • ,
  • Brad Schenkel, MS

      Affiliations

    • Worldwide Health Economics, Johnson & Johnson Pharmaceutical Services LLC, Horsham, Pennsylvania
    • ,
  • Philippe Szapary, MD, MSCE

      Affiliations

    • Centocor, Inc, Malvern, Pennsylvania
    • ,
  • Ming-Chun Hsu, PhD

      Affiliations

    • Centocor, Inc, Malvern, Pennsylvania
    • ,
  • Jean-Paul Ortonne, MD

      Affiliations

    • Hôpital L'Archet, Nice, France
    • ,
  • Kenneth B. Gordon, MD

      Affiliations

    • Northwestern University Feinberg School of Medicine and Evanston Northwestern Healthcare, Chicago, Illinois
    • ,
  • Alexa B. Kimball, MD, MPH

      Affiliations

    • Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Alexa B. Kimball, MD, MPH, Department of Dermatology, Harvard Medical School, 50 Staniford St, #246, Boston, MA 02114.

,Accepted 15 September 2009.

References 

  1. Sampogna F, Tabolli S, Abeni D. the IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study. Br J Dermatol. 2007;157:508–513
  2. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215:17–27
  3. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139:846–850
  4. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21:54–59
  5. Cohen AD, Ofek-Shlomai A, Vardy DA, Weiner Z, Shvartzman P. Depression in dermatological patients identified by the mini international neuropsychiatric interview questionnaire. J Am Acad Dermatol. 2006;54:94–99
  6. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch Gen Psychiatry. 1994;51:355–364
  7. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;287:203–209
  8. Evers AW, Lu Y, Duller P, van der Valk PG, Kraaimaat FW, van de Kerkhof PC. Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol. 2005;152:1275–1281
  9. Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol. 2006;54:420–426
  10. Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159:704–710
  11. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367:29–35
  12. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, et al. CNTO 1275 Psoriasis Study Group A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356:580–592
  13. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. PHOENIX 1 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674
  14. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684
  15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370
  16. Moorey S, Greer S, Watson M, Gorman C, Rowden L, Tunmore R, et al. The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer. Br J Psychiatry. 1991;158:255–259
  17. Snaith RP, Zigmond AS. The hospital anxiety and depression scale manual. Windsor: National Foundation for Educational Research (NFER)-NELSON; 1994.
  18. Herrmann C. International experiences with the hospital anxiety and depression scale–a review of validation data and clinical results. J Psychosom Res. 1997;42:17–41
  19. Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216
  20. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861–867
  21. Browall M, Ahlberg K, Karlsson P, Danielson E, Persson LO, Gaston-Johansson F. Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. Eur J Oncol Nurs. 2008;12:180–189
  22. Puhan MA, Frey M, Büchi S, Schünemann HJ. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6:46
  23. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407
  24. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–741
  25. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31
  26. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res. 2002;52:69–77
  27. Golden J, Conroy RM, O'Dwyer AM, Golden D, Hardouin JB. Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. Soc Sci Med. 2006;63:3188–3198
  28. Strik JJ, Honig A, Lousberg R, Denollet J. Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction. Psychosomatics. 2001;42:423–428
  29. van den Beuken-van Everdingen MH, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psychooncology. 2008;40:59–69
  30. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Gironell A, García-Sánchez C, Martínez-Corral M. Motor changes during sertraline treatment in depressed patients with Parkinson's disease. Eur J Neurol. 2008;15:953–959
  31. Siepman TA, Janssens AC, de Koning I, Polman CH, Boringa JB, Hintzen RQ. The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis. J Neurol. 2008;255:910–916
  32. Lambert J, Griffiths CEM, Dauden E, Boggs R, Estojak J, Robertson D. Sustained improvements in depression and anxiety symptoms with etanercept therapy for up to 54 weeks in patients with moderate to severe psoriasis: results of the CRYSTEL study. Abstract presented at: 17th European Academy of Dermatology and Venereology (EADV); September 17-21, 2008; Paris, France.
  33. Lewis V, Finlay AY. 10 Years experience of the dermatology life quality index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169–180
  34. Golden J, Conroy RM, O'Dwyer AM. Reliability and validity of the hospital anxiety and depression scale and the Beck depression inventory (full and fastscreen scales) in detecting depression in persons with hepatitis C. J Affect Disord. 2007;100:265–269
  35. Poole NA, Morgan JF. Validity and reliability of the hospital anxiety and depression scale in a hypertrophic cardiomyopathy clinic: the HADS in a cardiomyopathy population. Gen Hosp Psychiatry. 2006;28:55–58
  36. Silverstone PH. Poor efficacy of the hospital anxiety and depression scale in the diagnosis of major depressive disorder in both medical and psychiatric patients. J Psychosom Res. 1994;38:441–450

 Supported by Centocor, Inc.

 Disclosures can be found in the Appendix.

PII: S0190-9622(09)01197-9

doi: 10.1016/j.jaad.2009.09.014

Journal of the American Academy of Dermatology
Volume 63, Issue 3 , Pages 457-465 , September 2010

Article Tools

* Image Usage & Resolution